1260403-58-4

Upstream product

• 220607-75-0 2-bromo-1-(3,5-difluorophenyl)ethanone 
• 75-75-2 methanesulfonic acid 
• 60421-23-0 cycloleucine methyl ester hydrochloride 

Downstream Products

• 957187-34-7 C₁₆H₁₈F₂N₂O₃ 
• 1321609-36-2 C₁₉H₂₆F₂N₂O₄ 
• 1321609-25-9 C₁₉H₂₆F₂N₂O₇S 
• 1260403-59-5 C₁₅H₁₉F₂NO₃ 
• 1260403-60-8 CH₄O₃S*C₁₅H₁₉F₂NO₃ 
• 957118-49-9 [3H]-MK 3207 
• 957121-89-0 ethyl [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate 

Relevant academic research and scientific papers

PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST

The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.